10.04.2015 08:21:13

CellaVision's 2014 Annual Report now available

2015-04-10
English

Today, CellaVision announced that the company's Annual Report for 2014 is available as PDF at www.cellavision.com, and can be read via the link below.

To request a printed version, please visit the investor pages at CellaVision's website.

For more information, please contact:
Zlatko Rihter, CEO, CellaVision AB


Phone: +46 733 62 11 06 | E-mail: zlatko.rihter@cellavision.com


About CellaVision
CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products rationalize manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in image analysis, artificial intelligence and automated microscopy. In most countries sales are via global partners. Products are sold directly in the Nordic countries and via subsidiaries in the US, Canada and Japan. In 2014 sales were SEK 217 million and sales continue to increase, with a growth target of at least 15 % per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq OMX Stockholm, Small Cap list. Read more at www.cellavision.com.




This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Cellavision AB via Globenewswire

HUG#1910029

Analysen zu Cellavision ABmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Cellavision AB 18,50 0,98% Cellavision AB